Patent Application
20150265666
Disclosed here are antimicrobial compositions comprising mixtures of botanical extracts, synthetic antimicrobial agents and essential oils which do not rely solely upon alcohol to produce their antimicrobial effects.
The Centers for Disease Control and Prevention (CDC) have issued guidelines recommending the use of alcohol-based products (60-70% alcohol) for skin disinfection to reduce the transmission of pathogenic organisms to patients and personnel in health care settings. However, alcohol-based hand sanitizers, although effective in rapidly killing germs, disrupt the skin's moisture and pH balance by stripping away the natural oils, leaving the skin dry, cracked, and more susceptible to infections. Further, alcohol based sanitizers with 60-70% alcohol are highly flammable and can be misused with toxic consequences. According to a 2007 report published by the American Association of Poison Control Canter's, in 2006 there were approximately 12000 incidents of alcohol-poisoning directly attributed to alcohol based hand sanitizers.
There is a continuing desire for an antimicrobial composition which has a sufficiently low amount of alcohol to avoid the skin damage, flammability, and abuse potential of alcohol-dependent formulations (or which lacks alcohol altogether).
Described herein are antimicrobial compositions comprising mixtures of botanical extracts, synthetic antimicrobial agents and essential oils which do not rely solely upon alcohol to produce their antimicrobial effects.
In certain embodiments, an antimicrobial composition comprises (a) one or more essential oil or constituent thereof selected from thyme oil, thymol, fennel oil (e.g., fennel seed oil), vanilla oil and basil oil at a concentration of between about 0.01 and 0.5 percent weight/weight (“% w/w”); and (b) one or more synthetic antimicrobial selected from (i) biguanides, such as, for example, chlorhexidine free base or chlorhexidine salt (e.g. chlorhexidine gluconate or chlorhexidine acetate), polyhexamethylene biguanide (PHMB), polyaminipropyl biguanide (PAPB), and combinations thereof, at a concentration of between about 0.01 and 0.5% w/w; and (ii) quaternary ammonium compound, such as, for example, benzalkonium chloride (BAC), benzethonium chloride (BZT), cetyl pyridinium chloride, alkyl dimethyl benzyl ammonium chloride, dimethyl benzyl ammonium chloride, delmopinol hydrochloride, and combinations thereof, at a concentration of between about 0.02 and 0.5% w/w.
In certain non-limiting embodiments, an antimicrobial composition comprises (a) one or more plant extract, which may be vanilla extract, lemon extract, orange extract, grapefruit extract, grapefruit seed extract, Bacopa monniera (a.k.a. Brahmi) extract, honeysuckle extract, Echinacea (which may be Echinacea purpurea, Echinacea angustifolia or Echinacea pallida) extract, goldenseal (Hydrastis canadensis) extract, Portulaca oleracea extract, witchhazel extract, rosemary extract, stevia extract, tobacco extract, wasabi extract and/or willow bark extract, at a concentration of between about 0.1 and 1.0% w/w or between about 0.3 and 0.6% w/w; and (b) one or more synthetic antimicrobial, which may be a biguanide such as chlorhexidine free base or chlorhexidine salt (e.g. chlorhexidine gluconate or chlorhexidine acetate) or polyhexamethylene biguanide, a quaternary ammonium compound such as benzalkonium chloride (BAC), benzethonium chloride (BZT), or cetylpyridinium chloride (CPC), or delmopinol hydrochloride, at a concentration of between about 0.05 and 0.5% w/w; where said composition may comprise less than 21% w/w or less than 10% w/w or less than 5% w/w or less than 2% w/w or less than 1% w/w or less than 0.5% w/w or less than 0.01% w/w, or essentially no, alcohol; and/or no benzyl alcohol, and/or no ethanol, and/or no isopropyl alcohol. Said antimicrobial composition may optionally further comprise one or more of (i) an alkanediol which may be propanediol, pentanediol, hexanediol, heptanediol, octanediol, nonanediol or decandediol at a concentration between about 0 and 2.0% w/w or between about 0.01 and 2.0% w/w or between about 0.3 and 2.0% w/w; (ii) a solubulizer which may be a plant-based mild solubilizing non ionic surfactant, for example caprilyl capryl glucoside, decyl glucoside, or a combination thereof; (iii) a plant-based organic acid which may be lactic acid, citric acid, benzoic acid or a combination thereof (e.g., at a concentration of between about 0.1-0.5% w/w); (iv) an essential oil or constituent thereof which may be thymol, rosemary oil, lemongrass oil, cinnamon oil, pine oil, clove bud oil, basil oil, cedarwood oil, or a combination thereof (e.g. at a concentration of between about 0.05 and 0.5% w/w or between about 0.05 and 0.2% w/w or between about 0.1 and 0.2% w/w); (v) a botanical anti-irritant which may be aloe gel/extract (e.g. at a concentration between about 0.1-50% w/w); aloe leaf juice (e.g. at a concentration of between about 0.5-2.05% w/w); bisabolol (e.g. at a concentration between about 0.05-2.0% w/w); and/or an oat product such as beta glucan, oat kernel extract, or oat flour (e.g. at a concentration between about 0.2 and 3.0% w/w); (vi) an anti-inflammatory agent which may be calendula oil, rosemary oil, a curcumin compound (e.g. curcumin, desmethoxycurcumin, bis-desmethoxycurcumin, tetrahydrocurcuminoids), pomegranate oil, clove oil, Echinacea purpurea extract, resveratrol (e.g. at a concentration between about 0.1 and 0.5% w/w), portulaca extract and/or witchhazel extract (e.g. at a concentration up to about 2.0% w/w); (vii) a solvent which may be a solubilizer-containing mixture of PEG-40 hydrogenated castor oil, tridecath 9 and water (e.g. at a concentration between about 0.5 and 5.0% w/w), phenyl ethanol (e.g. at a concentration between about 0.3 and 1.0% w/w), and alcohol (e.g. at a concentration up to about 5% w/w or up to about 10% w/w or up to about 15% w/w or up to about 20% w/w or up to about 25% w/w); and/or (viii) an additional antimicrobial agent/anti biofilm agents which may be sodium pyrithion, zinc pyrithion, a silver salt such as silver nitrate, silver sulfadiazine, povidone iodine, xylitol, Germall plus (diazolidinyl urea and iodopropynyl butylcarbamate solubilized in propylene glycol), hypochlorite, hydrogen peroxide, urea hydrogen peroxide, sodium hypochlorite and/or triclosan.
In certain non-limiting embodiments, the antimicrobial composition described herein comprises: (i) a plant extract selected from the group consisting of vanilla extract, lemon extract, citrus extract, grapefruit seed extract and combinations thereof at a concentration of between about 0.01 and 5% w/w, or between about 0.05 and 1% w/w, or between about 0.1 and 0.6% w/w;
(ii) polyhexamethylene biguanide (PHMB), polyaminopropyl biguanide (PAPB) or combinations thereof at a concentration of between about 0.001 and 5% w/w, or between about 0.005 and 1% w/w, or between about 0.01 and 0.3% w/w; and
(iii) one or more essential oil or active ingredient thereof selected from the group consisting of lemongrass oil, lemon oil, fennel seed oil, orange oil, basil oil, cinnamon oil, thyme oil, clove oil, pine oil, cedar wood oil, thymol, farnesol, bisabolol, cinnamaldehyde, cinnamylacetic ester, cinnamic acid, ethyl cinnamate or combinations thereof, at a concentration of between about 0.001 and 5% w/w, or between about 0.005 and 1% w/w, or between about 0.01 and 0.5% w/w.
In certain embodiments, the PHMB is comprised in a Cosmocil composition. In certain embodiments, the Cosmocil composition comprises PHMB at a concentration of about 20% w/w.
In certain embodiments, the composition comprises vanilla extract, lemon extract or combinations thereof, and does not comprise any other citrus extract.
In certain non-limiting embodiments, the antimicrobial composition described herein further comprises: (iv) one or more alkanediol selected from the group consisting of propanediol, pentanediol, hexanediol, heptanediol, octanediol, decanediol, nonanediol and combinations thereof, at a concentration of between about 0 and 10% w/w, or between about 0 and 10% w/w, or between about 0 and 5% w/w, or between about 0.01 and 0.5% w/w;
(v) an organic acid selected from the group consisting of benzoic acid, lactic acid, citric acid and combinations thereof, at a concentration of between about 0.005 and 5% w/w, or between about 0.01 and 1% w/w, or between about 0.05 and 0.5% w/w;
(vi) a solvents which enhances the solubility of the ingredients of the composition, selected from the group consisting of alcohol (between about 0 and 80% w/w), phenyl ethanol (between about 0 and 1.0% w/w), a mixture of PEG-40 hydrogenated castor oil, Trideceth-9, propylene glycol and water (between about 0 and 2% w/w), a mixture of PEG-40 hydrogenated castor oil, Trideceth-9 and water (between about 0 and 2% w/w), caprylyl capryl glucoside (Plantasol) (between about 0 and 2% w/w), and combinations thereof;
(vii) one or more anti-irritant selected from the group consisting of zinc salicylate, basil oil, brahmi extract, red sandal wood extract, curcumin compound, aloe, bisabolol, rosemary oil, chalmogra oil, oat powder and/or extract, beta glucan, chitosan, calendula oil/extract, portulaca extract, witch hazel extract, pomegranate oil, at a concentration of between about 0.01 and 10% w/w, or between about 0.05 and 5% w/w, or between about 0.1 and 2% w/w.
In certain non-limiting embodiments, the antimicrobial composition described herein comprises: (i) a plant extract selected from the group consisting of vanilla extract, lemon extract and combinations thereof at a concentration of between about 0.1 and 1% w/w; (ii) one or more synthetic antimicrobial selected from the group consisting of polyhexamethylene biguanide (PHMB), polyaminopropyl biguanide (PAPB), and combinations thereof, at a concentration of between about 0.001 and 0.5% w/w; and (iii) one or more essential oil or constituent thereof selected from the group consisting of thyme oil, thymol, cinnamon oil, cinnamaldehyde, cinnamylacetic ester, cinnamic acid, ethyl cinnamate, fennel oil, basil oil, lemongrass oil, lemon oil, orange oil, clove oil, pine oil, cedarwood oil, rosemary oil, and combinations thereof, at a concentration of between about 0.01 and 0.5% w/w.
In certain non-limiting embodiments, the antimicrobial composition described herein comprises: (i) a plant extract selected from the group consisting of vanilla extract, lemon extract and combinations thereof at a concentration of between about 0.1 and 0.6% w/w; (ii) polyhexamethylene biguanide (PHMB) at a concentration of between about 0.01 and 0.3% w/w; and (iii) one or more essential oil or active ingredient thereof selected from the group consisting of thyme oil, cinnamon oil, thymol, cinnamaldehyde, cinnamylacetic ester, cinnamic acid, ethyl cinnamate or combinations thereof, at a concentration of between about 0.01 and 0.5% w/w.
In certain non-limiting embodiments, the antimicrobial composition described herein comprises essentially no benzyl alcohol.
Antimicrobial compositions disclosed herein may be used as preservative additives to other products (e.g. to oral care, personal care, household, veterinary or industrial products) or may themselves serve, with additional ingredients as known in the art, as personal care, household, veterinary or industrial products. Non-limiting examples include skin sanitizer/disinfectant (e.g. hand sanitizer, body wash) in the form of a lotion, foam, cream or wipe; surface sanitizer/disinfectant in the form of a liquid or wipe, veterinary sanitizer/disinfectant in the form of a liquid, foam, lotion, cream or wipe; oral care rinse; oral care wipe; oral care gel; oral care toothpaste; topical anti-itch treatment, anti-inflammatory gel/cream, wound care formulations which may be a lotion, cream, spray, wipe, or wound covering; or animal teat dip or wipe (e.g. cow teat dip or wipe).
As used herein, the term “chlorhexidine free base” means the basic form of chlorhexidine.
In certain embodiments, the weight percentages of the ingredients of the formulations described herein can be adjusted to provide for concentrated formulations that can be diluted prior to use. For example, the ingredients of the formulations described herein can be adjusted to concentrations of between about 1 and 25 times (1-25×) the % w/w identified in the formulations herein For example, the % w/w of the ingredients of the formulations described herein can be adjusted to concentrations of 1×, 2×, 3×, 4×, 5×, 6×, 7×, 8×, 9×, 10×, 15×, 20× or 25×, and values in between.
In the formulations disclosed herein, where the weight percentages of ingredients listed do not add up to 100 percent, the additional components may include components known in the art for an intended use, for example in personal care products, oral formulations, foods, beverages, and as topical or surface disinfectants. As non-limiting examples, the components may comprise one or more of water or other solvent, thickening agent(s), emollient(s), food product, etc., as the case may be.
Ranges specified herein include their recited limits; for example, a range of between 2 and 4 includes 2 and 4.
For clarity but not by way of limitation, the detailed description is divided into the following subsections,
(i) active agents;
(ii) oral formulations
(iii) topical disinfectants; and
(iv) surface disinfectants.
In certain non-limiting embodiments, an antimicrobial composition is provided comprising mixtures of botanical extracts, synthetic antimicrobial agents and essential oils which do not rely solely upon alcohol to produce their antimicrobial effects.
In certain embodiments, an antimicrobial composition comprises:
(a) one or more essential oil or constituent thereof selected from thyme oil, thymol, fennel oil (e.g., fennel seed oil), vanilla oil and basil oil at a concentration of between about 0.001 and about 1 percent weight/weight (“% w/w”), between about 0.01 and about 0.8% w/w, between about 0.1 and about 0.6% w/w, or between about 0.2 and about 0.5% w/w. In certain embodiments, the one or more essential oil or constituent thereof is at a concentration of between about 0.01 and about 0.5% w/w;
(b) one or more synthetic antimicrobial selected from (i) biguanides, such as, for example, chlorhexidine free base or chlorhexidine salt (e.g. chlorhexidine gluconate or chlorhexidine acetate), polyhexamethylene biguanide (PHMB), polyaminipropyl biguanide (PAPS), and combinations thereof, at a concentration of between about 0.001 and about 6% w/w, between about 0.001 and about 1% w/w, between about 0.001 and about 0.5% w/w, between about 0.01 and about 0.8% w/w, between about 0.01 and about 0.5% w/w, between about 0.1 and about 0.6% w/w, or between about 0.2 and about 0.5% w/w; (ii) quaternary ammonium compound, such as, for example, benzalkonium chloride (BAC), benzethonium chloride (BZT), cetyl pyridinium chloride, alkyl dimethyl benzyl ammonium chloride, dimethyl benzyl ammonium chloride, delmopinol hydrochloride, and combinations thereof, at a concentration of between about 0.001 and about 6% w/w, between about 0.001 and about 1% w/w, between about 0.001 and about 0.5% w/w, between about 0.01 and about 0.8% w/w, between about 0.02 and about 0.5% w/w, between about 0.1 and about 0.6% w/w, or between about 0.2 and about 0.5% w/w, and (iii) a hypochlorite, hydrogen peroxide, urea hydrogen peroxide, and combinations thereof, at a concentration of between about 0.001 and about 6% w/w, between about 0.001 and about 1% w/w, between about 0.001 and about 0.5% w/w, between about 0.01 and about 0.8% w/w, between about 0.02 and about 0.5% yaw, between about 0.1 and about 0.6% w/w, or between about 0.2 and about 0.5% w/w.
As used herein, the term “chlorhexidine free base” means the basic form of chlorhexidine.
In certain embodiments, the antimicrobial composition comprising one or more essential oil or constituent thereof and one or more synthetic antimicrobial comprises essentially no benzyl alcohol.
The antimicrobial composition comprising one or more essential oil or constituent thereof and one or more synthetic antimicrobial may optionally further comprise one or more of the following:
(c) one or more essential oil or constituent thereof selected from lemon grass oil, lemon oil, orange oil, basil oil, cinnamon oil, rosemary oil, peppermint oil, spearmint oil, eucalyptus oil, clove oil, pine oil, cedar wood oil, farnesol, and bisabolol at a concentration of between 0.01 and 0.7% w/w;
(d) one or more alkanediol selected from propanediol (e.g., Zemea®), pentanediol, hexanediol, heptanediol, octanediol, decanediol and nonanediol, at a concentration of between about 0.3 and 5.0% w/w;
(e) one or more organic acid selected from benzoic acid, lactic acid and citric acid, at a concentration of between about 0.05 and 0.5% w/w;
(f) one or more botanical extract such as a citrus extract, lemon extract, orange extract, grapefruit seed extract, grapefruit extract, and vanilla extract, at a concentration of between about 0 and about 5% w/w, between about 01 and about 1% w/w, or between about 0.1 and 0.6% w/w;
(g) one or more solvents and/or solubilizer selected from alcohol (e.g., ethyl alcohol or ethanol) (0-80% w/w), phenyl ethanol (0-1.0% w/w, or 0.3-1.0% w/w, or 25% w/w or less, or 20% w/w or less, or 15% w/w or less, or 10% w/w or less, or 5% w/w or less), PEG-40 hydrogenated Castor oil, trideceth-9, propylene glycol, water (0-2.0% w/w), caprylyl capryl glucoside (Plantasol) (0-2.0% w/w);
(h) one or more antimicrobial agent selected from sodium pyrithion, zinc pyrithion, silver salt (e.g., silver nitrate, and/or silver sulfadiazine), povidone iodine, Germall plus (diazolidinyl urea and iodopropynyl butylcarbamate solubilized in propylene glycol), and triclosan.
(i) one or more anti-irritant selected from brahmi extracts, red sandal wood extracts, curcumin compounds, aloe, bisabolol, rosemary oil, chalmogra oil, oat powder, oat extract, beta glucan, chitosan, calendula oil, portulaca extract, witch hazel extract, and pomegranate oil, at a concentration of between about 0.1 and 2.0% w/w.
In certain non-limiting embodiments, an antimicrobial composition is provided comprising (a) one or more plant/fruit extract which may be a citrus extract such as a lemon extract, orange extract, grapefruit seed extract or grapefruit extract or vanilla extract or a combination thereof (e.g. at a concentration between about 0.15 and 0.6% w/w); (b) one or more synthetic antimicrobial which may be a quaternary ammonium compound such as benzalkonium chloride, benzethonium chloride, cetyl pyrinidium chloride, alkyl dimethyl benzyl ammonium chloride or dimethyl benzyl ammonium chloride, a biguanide such as chlorhexidine free base or chlorhexidine salt (e.g. chlorhexidine gluconate or chlorhexidine acetate) or polyhexamethylene biguanide, or a combination thereof (e.g. at a concentration between about 0.05 and 0.5% w/w); (c) one or more essential oil or active ingredient thereof which may be thymol, rosemary oil, lemongrass oil, cinnamon oil, or a combination thereof (e.g. at a concentration of between about 0.05 and 0.5% w/w); (d) one or more plant-based mild solubilizing nonionic surfactant which may be caprilyl capryl glucoside, decyl glucoside, or a combination thereof (e.g. at a concentration of between about 0.3 and 10.0% w/w); (e) one or more plant-based organic acid which may be lactic acid, citric acid, benzoic acid, or a combination thereof (e.g. at a concentration between about 0.1 and 0.5% w/w); (f) one or more botanical anti-irritant which may be aloe gel/extract or leaf juice (e.g. at a concentration between about 0.1 and 2.0% w/w), bisabolol (e.g. at a concentration between about 0.05 and 1.0% w/w); and (g) one or more anti-inflammatory agent which may be calendula oil, rosemary oil, a curcumin compounds, pomegranate oil, Echinacea purpurea extract, resveratrol or a combination thereof (e.g. at a concentration of between about 0.1 and 0.5% w/w). Additional optional components of such compositions may include (i) one or more additional solvent such as a solubilizer-containing mixture of PEG-40 Hydrogenated castor oil, Tridecath 9 and water (e.g. at a concentration of between about 0.5 and 5.0% w/w), phenyl ethanol (e.g. at a concentration of between about 0.3 and 1.0% w/w); (ii) an alkanediol which may be pentanediol, hexanediol, heptanediol, octanediol, nonanediol, or decandediol (e.g. at a concentration of between about 0.3 and 1.05% w/w); (iii) an emollient which may be 1,3-propanediol, butylene glycol, propylene glycol, dipropylene glycol, glycerine, diglycerin, 2-methyl-1,3-propanediol (Solidol MP-D), or ethoxy diglycol (e.g. at a concentration of between about 0.5 and 5.0% w/w); (iv) a gelling agent which may be hydroxypropylmethyl cellulose, hydroxy propyl methyl cellulose stearoxy ether (Sangelose), chitosan, pyrrolidone carboxylate (Kytamer) (e.g. at a concentration between about 0.01 and 1.0% w/w); and/or (v) a silicone compound or product which may be isododecane and isononanoate (clearocast 550), dimethicone copolyol (Dow coming 2501 cosmetic wax), or silicone polyether copolymer (Dow coming 193 C fluid).
In certain non-limiting embodiments, the antimicrobial composition described herein comprises: (i) a plant extract selected from the group consisting of vanilla extract, lemon extract, citrus extract, grapefruit seed extract and combinations thereof at a concentration of between about 0.05 and 1% w/w, or between about 0.1 and 0.6% w/w;
(ii) polyhexamethylene biguanide (PHMB), polyaminopropyl biguanide (PAPB) or combinations thereof at a concentration of between about 0.001 and 5% w/w, or between about 0.005 and 1% w/w, or between about 0.01 and 0.3% w/w; and
(iii) one or more essential oil or active ingredient thereof selected from the group consisting of lemongrass oil, lemon oil, fennel seed oil, orange oil, basil oil, cinnamon oil, thyme oil, clove oil, pine oil, cedar wood oil, thymol, farnesol, bisabolol, cinnamaldehyde, cinnamylacetic ester, cinnamic acid, ethyl cinnamate or combinations thereof, at a concentration of between about 0.005 and 1% w/w, or between about 0.01 and 0.5% w/w.
In certain embodiments, the composition comprises vanilla extract, lemon extract or combinations thereof, and does not comprise any other citrus extract.
In certain non-limiting embodiments, the antimicrobial composition described herein further comprises: (iv) one or more alkanediol selected from the group consisting of propanediol, pentanediol, hexanediol, heptanediol, octanediol, decanediol, nonanediol and combinations thereof, at a concentration of between about 0 and 10% w/w, or between about 0 and 5% w/w, or between about 0.01 and 0.5% w/w;
(v) an organic acid selected from the group consisting of benzoic acid, lactic acid, citric acid and combinations thereof, at a concentration of between about 0.01 and 1% w/w, or between about 0.05 and 0.5% w/w;
(vi) a solvents which enhances the solubility of the ingredients of the composition, selected from the group consisting of alcohol (between about 0 and 80% w/w), phenyl ethanol (between about 0 and 1.0% w/w), a mixture of PEG-40 hydrogenated castor oil, Trideceth-9, propylene glycol and water (between about 0 and 2% w/w), a mixture of PEG-40 hydrogenated castor oil, Trideceth-9 and water (between about 0 and 2% w/w), caprylyl capryl glucoside (Plantasol) (between about 0 and 2% w/w), and combinations thereof;
(vii) one or more anti-irritant selected from the group consisting of zinc salicylate, basil oil, brahmi extract, red sandal wood extract, curcumin compound, aloe, bisabolol, rosemary oil, chalmogra oil, oat powder and/or extract, beta glucan, chitosan, calendula oil, portulaca extract, witch hazel extract, pomegranate oil, at a concentration of between about 0.05 and 5% w/w, or between about 0.1 and 2% w/w.
In certain non-limiting embodiments, the antimicrobial composition described herein comprises: (i) a plant extract selected from the group consisting of vanilla extract, lemon extract and combinations thereof at a concentration of between about 0.1 and 0.6% w/w; (ii) polyhexamethylene biguanide (PHMB) at a concentration of between about 0.01 and 0.3% w/w; and (iii) one or more essential oil or active ingredient thereof selected from the group consisting of thyme oil, cinnamon oil, thymol, cinnamaldehyde, cinnamylacetic ester, cinnamic acid, ethyl cinnamate or combinations thereof, at a concentration of between about 0.01 and 0.5% w/w.
In certain non-limiting embodiments, the antimicrobial composition described herein comprises:
(i) one or more plant extract selected from vanilla extract, lemon extract, orange extract, grapefruit seed extract, Bacopa monniera extract, honeysuckle extract, Echinacea extract, goldenseal (Hydrastis canadensis) extract, Portulaca oleracea extract, witchhazel extract, rosemary extract, stevia extract, tobacco extract, wasabi extract and/or willow bark extract, at a concentration of between about 0 and about 5.0% w/w, or between about 0.1 and about 1.0% w/w;
(ii) one or more synthetic antimicrobial selected from a biguanide such as chlorhexidine free base or chlorhexidine salt, polyhexamethylene biguanide, polyaminopropyl biguanide, and combinations thereof; a quaternary ammonium compound such as benzalkonium chloride (BAC), delmopinol hydrochloride, benzethonium chloride (BZT), cetylpyridinium chloride (CPC), dimethyl benzyl ammonium chloride, and combinations thereof; a hypochlorite, hydrogen peroxide, and combinations thereof; at a concentration of between about 0.001 and about 6.0% w/w and between about 0.001 and about 0.5% w/w;
(iii) essential oil or constituent thereof selected from thyme oil, thymol, cinnamon oil, cinnamaldehyde, cinnamylacetic ester, cinnamic acid, ethyl cinnamate, rosemary oil, lemongrass oil, lemon oil, orange oil, cinnamon oil, fennel oil, vanilla oil, basil oil, clove oil, farnesol, bisabalol, and combinations thereof, at a concentration of between about 0.001 and about 5% w/w or between about 0.01 and about 0.5% w/w; and
(iv) essentially no benzyl alcohol.
In certain specific embodiments, a pure vanilla extract is incorporated into an antimicrobial composition. Pure Vanilla Extract may be manufactured in accordance with the U.S. standard of identify. Vanilla is the only flavor that has a standard of identity. This means, by law vanilla extract can only contain certain ingredients to be labeled as pure. The standard of identity requires 13.35 ounces of cured, cut vanilla beans (with a moisture content not greater than 25.00%) be used per gallon of finished extract. The extract must contain a minimum 35.00% alcohol by volume.
In certain specific embodiments, a pure lemon extract is incorporated into an antimicrobial composition. Pure Lemon Extract may be prepared by alcohol/water extraction of fresh lemon. The extract major ingredient is lemon oil.
In certain non-limiting embodiments, the pH of the compositions described herein are at a pH of between about 3 and 6, or between about 3.5 and 5.5 or between about 4 and 5. Any method known in the art may be used to adjust the pH of a composition referred to herein. In specific non-limiting embodiments, sodium hydroxide or triethanolamine may be added to increase the pH. In specific non-limiting embodiments, organic acids such as lactic acid, citric acid, and/or benzoic acid may be added to decrease the pH.
In certain embodiments, the compositions described herein are oral care compositions for use in reducing the number and/or growth of microbes in the mouth of a subject. Also provided is a method of reducing the number and/or growth of microbes in the mouth of a subject comprising applying the oral care composition to an inside surface of the mouth of the subject.
In certain non-limiting embodiments, the oral composition described herein comprises: (i) a plant extract selected from the group consisting of vanilla extract, lemon extract, citrus extract, grapefruit seed extract and combinations thereof at a concentration of between about 0.05 and 1% w/w, or between about 0.1 and 0.6% w/w;
(ii) polyhexamethylene biguanide (PHMB), polyaminopropyl biguanide (PAPB) or combinations thereof at a concentration between about 0.001 and 5% w/w, or between about 0.005 and 1% w/w, or between about 0.01 and 0.3% w/w; and
(iii) one or more essential oil or active ingredient thereof selected from the group consisting of lemongrass oil, lemon oil, fennel seed oil, orange oil, basil oil, cinnamon oil, thyme oil, clove oil, pine oil, cedar wood oil, thymol, farnesol, bisabolol, cinnamaldehyde, cinnamyl acetic ester, cinnamic acid, ethyl cinnamate or combinations thereof, at a concentration of between about 0.005 and 1% w/w, or between about 0.01 and 0.5% w/w.
In certain embodiments, the composition comprises vanilla extract, lemon extract or combinations thereof, and does not comprise any other citrus extract.
In certain non-limiting embodiments, the composition described herein further comprises: (iv) one or more alkanediol selected from the group consisting of propanediol, pentanediol, hexanediol, heptanediol, octanediol, decanediol, nonanediol and combinations thereof, at a concentration of between about 0 and 10% w/w, or between about 0 and 5% w/w, or between about 0.01 and 0.5% w/w;
(v) an organic acid selected from the group consisting of benzoic acid, lactic acid, citric acid and combinations thereof, at a concentration of between about 0.01 and 1% w/w, or between about 0.05 and 0.5% w/w;
(vi) a solvents which enhances the solubility of the ingredients of the composition, selected from the group consisting of alcohol (between about 0 and 80% w/w), phenyl ethanol (between about 0 and 1.0% w/w), a mixture of PEG-40 hydrogenated castor oil, Trideceth-9, propylene glycol and water (between about 0 and 2% w/w), a mixture of PEG-40 hydrogenated castor oil, Trideceth-9 and water (between about 0 and 2% w/w), caprylyl capryl glucoside (Plantasol) (between about 0 and 2% w/w), and combinations thereof;
(vii) one or more anti-irritant selected from the group consisting of zinc salicylate, basil oil, brahmi extract, red sandal wood extract, curcumin compound, aloe, bisabolol, rosemary oil, chalmogra oil, oat powder and/or extract, beta glucan, chitosan, calendula oil, portulaca extract, witch hazel extract, pomegranate oil, at a concentration of between about 0.05 and 5% w/w, or between about 0.1 and 2% w/w.
In certain non-limiting embodiments, the composition described herein comprises: (i) a plant extract selected from the group consisting of vanilla extract, lemon extract and combinations thereof at a concentration of between about 0.1 and 0.6% w/w; (ii) polyhexamethylene biguanide (PHMB) at a concentration of between about 0.01 and 0.3% w/w; and (iii) one or more essential oil or active ingredient thereof selected from the group consisting of thyme oil, cinnamon oil, thymol, cinnamaldehyde, cinnamylacetic ester, cinnamic acid, ethyl cinnamate or combinations thereof, at a concentration of between about 0.01 and 0.5% w/w.
In certain non-limiting embodiments, an oral care rinse, gel or toothpaste is provided comprising (a) one or more plant/fruit extract which may be citrus extract (e.g. lemon extract, grapefruit seed extract), vanilla extract, wasabi extract or a combination thereof (e.g. at a concentration of between about 0.1 and 0.6% w/w); (b) one or more synthetic antimicrobial which may be cetyl pyrinidium chloride or a biguanide such as chlorhexidine free base or chlorhexidine salt (e.g. chlorhexidine gluconate or chlorhexidine acetate) or polyhexamethylene biguanide, polyaminopropyl biguanide, or a combination thereof (e.g. at a concentration of between about 0.05 and 0.5% w/w); (c) one or more alkanediol which may be propanediol, pentanediol or a combination thereof (e.g. at a concentration between about 0.5 and 5.0% w/w or between about 0.5 and 2.0% w/w); (d) one or more essential oil or constituent thereof which may be thymol, a structural isomer of thymol (such as, for example, carvacrol or dekasol BL (e.g., o-Cymen-5-ol)), rosemary oil, cinnamon oil, clove bud oil, basil oil, or a combination thereof (e.g. at a concentration between about 0.05-0.5% w/w); (e) one or more flavoring agent which may be spearmint oil, peppermint oil, menthol, or a combination thereof (e.g. at a concentration between about 0.0-0.2% w/w); (f) one or more plant-based mild solubilizing non-ionic surfactant, for example caprilyl capryl glucoside or decyl glucoside (e.g. at a concentration between about 0.3 and 10.0% w/w); (g) one or more plant-based organic acid which may be lactic acid, citric acid, benzoic acid or a combination thereof (e.g. at a concentration between about 0.1 and 0.5% w/w); (h) one or more botanical anti-irritant, for example aloe gel/extract (e.g. at a concentration between about 0.1 and 1.0% w/w); and/or (i) one or more anti-inflammatory agent which may be calendula oil, rosemary oil, a curcumin compound (e.g. a tetrahydrocurcuminoid compound), pomegranate oil, Echinacea purpurea extract, Portulaca extract, resveratrol, zinc salicylate or a combination thereof (e.g. at a concentration between about 0.1 and 0.5% w/w). Said composition may optionally further comprise one or more of (i) an alcohol at a concentration up to about 25% w/w or up to about 20% w/w or up to about 15% w/w or up to about 10% w/w or up to about 5% w/w; (ii) a solubilizer containing mixture of PEG-40 Hydrogenated castor oil, Tridecath 9 and water (e.g. at a concentration between about 0.5 and 5.0% w/w); (iii) one or more emollient which may be propylene glycol, dipropylene glycol, glycerin, diglycerin or a combination thereof (e.g. at a concentration between about 0.5 and 10.0% w/w); (iv) one or more gelling agent which may be hydroxypropylmethyl cellulose, hydroxy propyl methyl cellulose stearoxy ether (Sangelose), chitosan, pyrrolidone carboxylate (Kytamer), Poloxamer (pluronic gel) or a combination thereof (e.g. at a concentration between about 0.01 and 1.0% w/w); and/or (v) a sweetener, for example a sucralose-based sweetener such as Splenda, xylitol, and/or sorbitol.
In certain non-limiting embodiments, a botanical oral rinse is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a botanical oral rinse is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In certain non-limiting embodiments, a botanical oral rinse is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a botanical oral rinse is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In certain non-limiting embodiments, a botanical oral rinse is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a botanical oral rinse is provided comprising the following concentrations within the ranges set forth in the preceding paragraph
In a specific non-limiting embodiment, a botanical oral rinse is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In a specific non-limiting embodiment, a botanical oral rinse is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In certain non-limiting embodiments, a botanical oral rinse is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a botanical oral rinse is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In certain non-limiting embodiments, a botanical oral gel is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a botanical oral gel is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In a specific non-limiting embodiment, a botanical oral rinse is provided (referred to as “OCP-G1”) comprising the following concentrations, where phases A and B may be prepared separately then mixed:
In a specific non-limiting embodiment, a botanical oral rinse is provided (referred to as “OCP-G1”) comprising the following concentrations, where phases A and B may be prepared separately then mixed:
In a specific non-limiting embodiment, a botanical oral rinse is provided (referred to as “OCP-G2”) comprising the following concentrations, where phases A and B may be prepared separately and then mixed:
In a specific non-limiting embodiment, a botanical oral rinse is provided (referred to as “OCP-G2*”) comprising the following concentrations, where phases A and B may be prepared separately then mixed:
In a specific non-limiting embodiment, a botanical oral rinse with anti-inflammatory activity is provided (referred to as “OCP-AIF”) comprising the following concentrations, where phases A and B may be prepared separately and then mixed:
In a specific non-limiting embodiment, a botanical oral rinse with anti-inflammatory activity is provided (referred to as “OCP-AIF*”) comprising the following concentrations, where phases A and B may be prepared separately and then mixed:
In a specific non-limiting embodiment, a botanical oral rinse (referred to as “OCP-M20”) is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a botanical oral rinse (referred to as OCP-M20-1) is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In a specific non-limiting embodiment, a botanical oral rinse (referred to as “OCP-M21”) is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a botanical oral rinse (referred to as OCP-M21-1) is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In a specific non-limiting embodiment, a botanical oral rinse (referred to as “OCP-AIFCT4”) is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a botanical oral rinse (referred to as “OCP-AIFCT4-1”) is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse OCP-1”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse OCP-M”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “6B”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “7B”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “8B”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “15BCF”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “A2”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “16BCF”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “BOR-1”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17BCF.1”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17BCF.2”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17BCF-1”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17BCF-2”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17BCF-2.2”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17BCF-2A”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17BCF-1A”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 18BCF.1”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 18BCF.2”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 19BCF-1”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 19BCF-1A”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 19BCF-2A”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 19BCF.2”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 19BCF-2”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse A3.1”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse A3.2”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17A.1”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17A.2”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17BCF-C.1”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17BCF-C.2”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17A-C.1”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “Oral rinse 17A-C.2”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse is provided with a general formula comprising the following range of ingredients
In a specific non-limiting embodiment, an oral rinse (referred to as “PTFV1 Oral Rinse”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “PTFV2 Oral Rinse”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “PTFV-E1 Oral Rinse”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “PTFV-E2 Oral Rinse”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “CTFV Oral Rinse”) is provided comprising the following:
In a specific non-limiting embodiment, an oral rinse (referred to as “CTFV-E Oral Rinse”) is provided comprising the following:
Disclosed herein are compositions that may be comprised in disinfectant compositions that may be used to topically to reduce the number and/or growth of microbes on the skin of a human or non-human animal. The disinfectant may be a wash solution, a lotion, a cream, or a splash and/or may be comprised in a wipe. These compositions described herein can be used in, for example, skin sanitizers, wound care products and other personal and health care products. This composition can also be used to enhance the activity of products containing preservative or low alcohol (1-21%). The compositions described herein can also be used in veterinary products, for example, in a cow teat disinfectant or a mastitis cream.
The disinfectant composition comprises the recited active agents and a suitable solvent. Non-limiting examples of suitable solvents include water, ethanol, glycerin, octoxyglycerin, and mixtures thereof.
Disclosed herein is a method of reducing the number and/or growth of microbes on the skin of a subject comprising applying to the skin a topical disinfectant composition as set forth herein. Microbes, the numbers and/or growth of which are reduced, include but are not limited to one or more of Staphylococcus aureus (including methicillin resistant Staphylococcus aureus), Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, Aspergillus niger and Listeria monocytogenes.
In certain non-limiting embodiments, a topical antimicrobial/anti irritant/anti-inflammatory gel composition is provided comprising (a) one or more plant/fruit extract which may be a citrus extract, lemon extract, orange extract, grapefruit seed extract or grapefruit extract, vanilla extract, or a combination thereof (e.g. at a concentration of between about 0.15 and 0.6% w/w or between about 0.1% and 5% w/w); (b) one or more synthetic antimicrobial which may be a quaternary ammonium compound such as benzalkonium chloride, benzethonium chloride, or cetyl pyrinidium chloride, a biguanide such as chlorhexidine free base or chlorhexidine salt (e.g. chlorhexidine gluconate or chlorhexidine acetate) or polyhexamethylene biguanide, or a combination thereof (e.g. at a concentration between about 0.05% and 0.2% w/w or between about 0.2% and 5.0% w/w); (c) one or more essential oil or ingredient thereof which may be thymol, orange oil, rosemary oil, lemongrass oil, cinnamon oil, or a combination thereof (e.g. at a concentration between about 0.05 and 0.5% w/w or between about 0.5 and 4.0% w/w); (d) one or more botanical anti-irritant which may be aloe gel/extract (e.g. at a concentration between about 0.1 and 50% w/w), aloe leaf juice (e.g. at a concentration between about 0.5 and 2.0% w/w), bisabolol (e.g. at a concentration between about 0.05 and 2.0% w/w), an oat product such as beta glucan, oat kernel extract, or oat flour (e.g. at a concentration between about 0.2 and 3.0% w/w), and combinations thereof; (e) one or more anti-inflammatory agent which may be calendula oil, rosemary oil, a curcumin compound, pomegranate oil, Echinacea purpurea extract, portulaca extract, resveratrol, and combinations thereof (e.g. at a concentration between about 0 and 0.1% w/w or between about 0.1 and 0.5% w/w); (f) one or more alkanediol selected from the group consisting of propanediol, pentanediol, hexanediol, heptanediol, octanediol, decanediol, nonanediol and combinations thereof, at a concentration of between about 0 and 10% w/w, or between about 0 and 5% w/w, or between about 0.01 and 0.5% w/w and (g) an organic acid selected from the group consisting of benzoic acid, lactic acid, citric acid and combinations thereof, at a concentration of between about 0.01 and 1% w/w, or between about 0.05 and 0.5% w/w, or between about 0.25 and 2.0% w/w. Additional optional components of such compositions may include (i) an antioxidant such as tocopherol acetate or ascorbic acid; (ii) an emollient which may be 1,3-propanediol, butylene glycol, propylene glycol, glycerine, octoxyglycerine, or a combination thereof (e.g. at a concentration of between about 0.5 and 6.0% w/w or between about 3.0 and 30.0% w/w); and/or (iii) a gelling agent which may be hydroxypropylmethyl cellulose, hydroxy propyl methyl cellulose stearoxy ether (Sangelose), chitosan, pyrrolidone carboxylate (Kytamer) (e.g. at a concentration of between about 0.01 and 1.0% w/w)
In certain non-limiting embodiments, the topical composition described herein comprises: (i) a plant extract selected from the group consisting of vanilla extract, lemon extract, citrus extract, grapefruit seed extract and combinations thereof at a concentration of between about 0.05 and 1% w/w, or between about 0.1 and 0.6% w/w;
(ii) polyhexamethylene biguanide (PHMB), polyaminopropyl biguanide (PAPB) or combinations thereof at a concentration of between about 0.001 and 5% w/w, or between about 0.005 and 1% w/w, or between about 0.01 and 0.3% w/w; and
(iii) one or more essential oil or active ingredient thereof selected from the group consisting of lemongrass oil, lemon oil, fennel seed oil, orange oil, basil oil, cinnamon oil, thyme oil, clove oil, pine oil, cedar wood oil, thymol, farnesol, bisabolol, cinnamaldehyde, cinnamylacetic ester, cinnamic acid, ethyl cinnamate or combinations thereof, at a concentration of between about 0.005 and 1% w/w, or between about 0.01 and 0.5% w/w.
In certain embodiments, the composition comprises vanilla extract, lemon extract or combinations thereof, and does not comprise any other citrus extract.
In certain non-limiting embodiments, the composition described herein further comprises: (iv) one or more alkanediol selected from the group consisting of propanediol, pentanediol, hexanediol, heptanediol, octanediol, decanediol, nonanediol and combinations thereof, at a concentration of between about 0 and 10% w/w, or between about 0 and 5% w/w, or between about 0.01 and 0.5% w/w;
(v) an organic acid selected from the group consisting of benzoic acid, lactic acid, citric acid and combinations thereof, at a concentration of between about 0.01 and 1% w/w, or between about 0.05 and 0.5% w/w;
(vi) a solvents which enhances the solubility of the ingredients of the composition, selected from the group consisting of alcohol (between about 0 and 80% w/w), phenyl ethanol (between about 0 and 1.0% w/w), a mixture of PEG-40 hydrogenated castor oil, Trideceth-9, propylene glycol and water (between about 0 and 2% w/w), a mixture of PEG-40 hydrogenated castor oil, Trideceth-9 and water (between about 0 and 2% w/w), caprylyl capryl glucoside (Plantasol) (between about 0 and 2% w/w), and combinations thereof;
(vii) one or more anti-irritant selected from the group consisting of zinc salicylate, basil oil, brahmi extract, red sandal wood extract, curcumin compound, aloe, bisabolol, rosemary oil, chalmogra oil, oat powder and/or extract, beta glucan, chitosan, calendula oil, portulaca extract, witch hazel extract, pomegranate oil, at a concentration of between about 0.05 and 5% w/w, or between about 0.1 and 2% w/w.
In certain non-limiting embodiments, the composition described herein comprises: (i) a plant extract selected from the group consisting of vanilla extract, lemon extract and combinations thereof at a concentration of between about 0.1 and 0.6% w/w; (ii) polyhexamethylene biguanide (PHMB) at a concentration of between about 0.01 and 0.3% w/w; and (iii) one or more essential oil or active ingredient thereof selected from the group consisting of thyme oil, cinnamon oil, thymol, cinnamaldehyde, cinnamylacetic ester, cinnamic acid, ethyl cinnamate or combinations thereof, at a concentration of between about 0.01 and 0.5% w/w.
“Hand sanitizers” is a term used herein to refer to skin sanitizers, which also may be used as topical disinfectants for skin of non-human animals.
In certain non-limiting embodiments, hand sanitizer products are provided as follows.
In certain non-limiting embodiments, a hand sanitizer foam is provided comprising the following:
In certain non-limiting embodiments, a hand sanitizer foam is provided comprising the following:
In certain non-limiting embodiments, a band sanitizer foam is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a hand sanitizer foam is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In certain non-limiting embodiments, a botanical hand sanitizer foam is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a hand sanitizer foam is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In a specific non-limiting embodiment, a hand sanitizer foam is provided comprising the following concentrations within the ranges set forth in paragraph preceding the paragraph immediately above:
In certain non-limiting embodiments, a hand sanitizer foam is provided comprising the following ranges of ingredients:
In certain non-limiting embodiments, a hand sanitizer foam is provided comprising the following ingredients:
In a specific non-limiting embodiment, a hand sanitizer lotion is provided comprising the following concentrations:
In a specific non-limiting embodiment, a hand sanitizer lotion is provided comprising the following concentrations:
In a specific non-limiting embodiment, a hand sanitizer lotion is provided comprising the following concentrations:
In a specific non-limiting embodiment, a hand sanitizer lotion is provided comprising the following:
In a specific non-limiting embodiment, a hand sanitizer lotion is provided comprising the following range of ingredients.
In a specific non-limiting embodiment, a hand sanitizer lotion is provided comprising the following:
In certain non-limiting embodiments, an anti-inflammatory, anti-irritant topical gel is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, an anti-inflammatory, anti-irritant topical gel is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In a specific non-limiting embodiment, an anti-inflammatory, anti-irritant topical gel is provided comprising the following:
In a specific non-limiting embodiment, an anti-inflammatory, anti-irritant topical gel is provided comprising the following ingredients:
In certain non-limiting embodiments, a topical wound-healing gel is provided comprising the following ranges of ingredients:
Said gel can be applied on the wound directly and/or incorporated in a wound dressing.
In a specific non-limiting embodiment, a topical wound-healing gel is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
Said gel can be applied on the wound directly and/or incorporated in a wound dressing.
In a specific non-limiting embodiment, a botanical hand disinfectant soap is provided comprising the following concentrations:
In certain non-limiting embodiments, a hand disinfectant soap (referred to as “SynBotanica-1”) is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a hand disinfectant soap (referred to as “SynBotanica-1A”) is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In certain non-limiting embodiments, a hand disinfectant soap (referred to as “SynBotanica-2”) is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a hand disinfectant soap (referred to as “SynBotanica-2A”) is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In certain non-limiting embodiments, a hand disinfectant soap (referred to as “SynBotanica-3”) is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a hand disinfectant soap (referred to as “SynBotanica-3A”) is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In certain non-limiting embodiments, a first aid cream (referred to as “SynBotanica First Aid Cream”) is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a first aid cream (referred to as “SynBotanica First Aid Cream”) is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In any of the formulations above, the percentage of water is intended to bring the total percentage of other ingredients up to 100.
In certain non-limiting embodiments, a body wash (referred to as “SynBotanica body wash-10”) is provided comprising the following ranges of ingredients:
In a specific non-limiting embodiment, a body wash (“SynBotanica body wash-10”) is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
In a specific non-limiting embodiment, a hand sanitizer aqueous foam (“Hand sanitizer aqueous foam”) is provided comprising the following ingredients:
In a specific non-limiting embodiment, an aqueous hand sanitizer lotion (“Aqueous Hand Sanitizer Lotion-1”) is provided comprising the following ingredients:
In a specific non-limiting embodiment, an aqueous hand sanitizer lotion (“Aqueous Hand Sanitizer Lotion-2”) is provided comprising the following ingredients:
In a specific non-limiting embodiment, a hand disinfectant soap (“Hand disinfectant Soap-1”) is provided comprising the following ingredients:
In a specific non-limiting embodiment, a hand disinfectant soap (“Hand disinfectant Soap-2”) is provided comprising the following ingredients:
In a specific non-limiting embodiment, a hand disinfectant soap (“Hand disinfectant Soap”) is provided comprising the following range of ingredients:
In a specific non-limiting embodiment, a hand disinfectant soap (“Hand disinfectant Soap”) is provided comprising the following ingredients:
In a specific non-limiting embodiment, a cow teat disinfectant solution is provided comprising the following ingredients:
In a specific non-limiting embodiment, a hand disinfectant soap (“HAND DISINFECTANT SOAP-SBW-1”) is provided comprising the following ingredients:
In a specific non-limiting embodiment, an Aqueous Hand Sanitizer Lotion (“SBW lotion-2”) is provided comprising the following ingredients:
In a specific non-limiting embodiment, an anti-inflammatory, anti-irritant topical gel (“SynBotanica Anti-inflammatory, anti-irritant topical gel SB AI-3”) is provided comprising the following ingredients:
In certain non-limiting embodiments, a cow teat disinfectant (CT) is provided comprising the following range of ingredients:
In certain non-limiting embodiments, a cow teat disinfectant (“CT-43”) is provided comprising the following:
In certain non-limiting embodiments, a cow teat disinfectant (“CT-49”) is provided comprising the following:
In certain non-limiting embodiments, a cow teat disinfectant (“CT-51”) is provided comprising the following:
In certain non-limiting embodiments, a mastitis cream is provided comprising the following:
Disclosed herein are compositions that may be comprised in disinfectant compositions that may be used to topically to reduce the number and/or growth of microbes on inanimate surfaces, for use in disinfecting, for example and not by way of limitation, hard surfaces such as floors, countertops, sinks, toilets, shower stalls, tables, furniture, car interiors, baby furniture, etc. as well as soft surfaces but non-absorbent surfaces such as leather or vinyl.
The disinfectant composition comprises the recited active agents and a suitable solvent. Non-limiting examples of suitable solvents include water, ethanol, glycerin, octoxyglycerin, and mixtures thereof.
Disclosed herein is a method of reducing the number and/or growth of microbes on an inanimate surface comprising applying to the surface a disinfectant composition as set forth herein. Microbes, the numbers and/or growth of which are reduced, include but are not limited to one or more of Staphylococcus aureus (including methicillin resistant Staphylococcus aureus), Staphylococcus epidermidis, Escherichia cob, Pseudomonas aeruginosa, Candida albicans, Aspergillus niger and Listeria monocytogenes.
In certain non-limiting embodiments, a hard surface disinfecting agent is provided comprising (a) one or more plant/fruit extract selected from the group consisting of citrus extract, cedarwood extract, lemon extract or grapefruit seed extract, vanilla extract or a combination thereof (e.g. at a concentration between about 0.1 and 0.6% w/w or at a concentration between about 0.0 and 2.0% w/w); (b) one or more synthetic antimicrobial which may be a quaternary ammonium compound such as benzalkonium chloride, benzethonium chloride, or cetyl pyrinidium chloride, a biguanide such as chlorhexidine free base or chlorhexidine salt (e.g. chlorhexidine gluconate or chlorhexidine acetate) or polyhexamethylene biguanide, or a combination thereof (e.g. at a concentration between about 0.01 and 1.0% w/w); (c) one or more essential oil or constituent thereof which may be thymol, lemongrass oil, pine oil, cedarwood oil or a combination thereof (e.g. at a concentration between about 0.01 and 5.0% w/w); (d) one or more plant based organic acid which may be lactic acid, citric acid, benzoic acid, or a combination thereof (e.g. at a concentration between about 0.1 and 5.0% w/w or at a concentration between about 5.0 and 20.0% w/w); and (e) one or more eco friendly surfactant, for example an alkyl polyglucoside, capryl glucoside, a cationic surfactant blend, or a non-ionic surfactant blend.
In certain non-limiting embodiments, a surface disinfectant is provided comprising the following ranges of ingredients:
In certain non-limiting embodiments, a surface disinfectant is provided comprising the following ranges of ingredients:
The above solution may be diluted with water, for example in a ratio between about 1:5 and 1:10, prior to use.
In a specific non-limiting embodiment, a surface disinfectant is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
The above solution may be diluted with water, for example in a ratio between about 1:5 and 1:10, prior to use.
In a specific non-limiting embodiment, a Surface Disinfectant General formula 1 is provided comprising the following ranges of ingredients:
The above solution may be diluted with water, for example, in a ratio between about 1:5 and 1:10, prior to use.
In a specific non-limiting embodiment, a Specific formulation 1A is provided comprising the following concentrations within the ranges set forth in the preceding paragraph:
The above solution may be diluted with water, for example, in a ratio between about 1:5 and 1:10, prior to use.
The antibacterial activity of various test formulations were tested. The test formulations were prepared by adding active agents to the following base formulation, in the concentrations listed in Table 1. Active ingredients were lemongrass oil (“LG”), cinnamon bark oil (“CN”), thymol (“T”), benzalkanoium chloride (“BAC”), polyhexamethylene biguanide (“PHMB”) and octanediol (“O”). Where needed water was added to bring the concentration to 100%.
Antibacterial activity against methicillin-resistant Staphylococcus aureus (“MRSA”) was tested using a 15 second exposure time (hereafter, “MRSA Rapid-Kill Assay”). Briefly, a tube-dilution method was used to evaluate samples as per the US FDA-Tentative Final Monograph (“TFM”) method. 0.9 ml of test sample was added to 0.1 ml of a bacterial culture containing 1×107 colony forming units per ml [cfu/ml] and vortexed for 15 seconds. 9 ml of Drug Neutralizing fluid (DNF) was added to neutralize activity, diluted serially and 0.5 ml plated on TSA plates. Plates were incubated for 18-24 hrs at 37° C. Base formulation without additives was used as a control in place of test sample and processed similarly. The antibacterial activity was determined by calculating the difference in log10 cfu/ml of test samples relative to control [PBS]. The results are shown in Table 1.
Control growth ranged from 5×105-1×106. It was observed that BAC enhanced the activity of essential oil mixtures containing thymol; BAC+ octanediol further enhanced the activity of LG+CN+ T; and PHMB at 0.06% showed synergistic activity with essential oils.
The antibacterial activity of various test formulations were tested. The test formulations were prepared by adding active agents to the following base formulation, in the concentrations listed in Table 2. Active ingredients were benzalkanoium chloride (“BAC”), polyhexamethylene biguanide (“PHMB”), lemon extract (“LE”), wasabi extract (“W”), and aspen bark extract (“A”). Where necessary water was added to bring the total concentration to 100%.
Antibacterial activity against methicillin-resistant Staphylococcus aureus (“MRSA”) was tested using a 15 second exposure time (hereafter, “MRSA Rapid-Kill Assay”). Briefly, a tube-dilution method was used to evaluate samples as per the US FDA-Tentative Final Monograph (“TFM”) method. 0.9 ml of test sample was added to 0.1 ml of a bacterial culture containing 1×107 colony forming units per ml [cfu/ml] and vortexed for 15 seconds. 9 ml of Drug Neutralizing fluid (DNF) was added to neutralize activity, diluted serially and 0.5 ml plated on TSA plates. Plates were incubated for 18-24 hrs at 37° C. Base formulation without additives was used as a control in place of test sample and processed similarly. The antibacterial activity was determined by calculating the difference in log 10 cfu/ml of test samples relative to control [PBS]. The results are shown in Table 2.
Control growth ranged from 5×105-1×106. It was observed that lemon extract showed enhanced activity with BAC
The antibacterial activity of various test formulations was tested. The test formulations were prepared by adding active agents (see Table 3) to the same base formulation used in the preceding example section. Active ingredients were citrus extract (lemon and grapefruit seed extracts), cinnamon bark oil (“CN”), thymol (“T”), clove bud oil (“CL”), pentanediol (“P”) and polyhexamethylene biguanide (“PHMB”). Where necessary water was added to bring the total concentration to 100%.
For oral care products, PHMB is preferred because BAC can produce mucosal irritation. PHMB is effective against gram negative bacteria. Therefore P. aeruginosa which is a gram negative organism was used in these tests. An agar-plate method was used/0.5 ml of the test sample was spread on TSA plates and for control PBS was used in the plate. These plates were incubated for 1 hr in the incubator at temperature 37±1° C. After 1 hr, the plates were taken out of the incubator and inoculated with 0.5 ml of 1×103 cfu/ml culture of P. aeruginosa. The plates were incubated for 18-24 hrs at 37±1° C. The antibacterial activity was determined by calculating the difference in log 10 colony-forming units (cfu) between control and test samples (i.e., log 10 reduction). The results are shown in Table 3 w.
Control growth ranged from 5×105-1×106. It was observed that PHMB and pentanediol enhanced the activity of low concentrations of essential oils and lemon extract.
The antibacterial activity of various test formulations were tested. The test formulations were prepared by adding active agents to the same base formulation used above, in the concentrations listed in Table 4. Active ingredients were lemongrass oil (“LG”), cinnamon bark oil (“CN”), thymol (“T”), benzalkonium chloride (“BAC”), polyhexamethylene biguanide (“PHMB”), lemon extract (“LE”), and octanediol (“0”). Where necessary water was added to bring the total concentration to 100%.
Antibacterial activity against methicillin-resistant Staphylococcus aureus (“MRSA”) was tested using a 15 second exposure time (hereafter, “MRSA Rapid-Kill Assay”). Briefly, a tube-dilution method was used to evaluate samples as per the US FDA-Tentative Final Monograph (“TFM”) method. 0.9 ml of test sample was added to 0.1 ml of a bacterial culture containing 1×107 colony forming units per ml [cfu/ml] and vortexed for 15 seconds. 9 ml of Drug Neutralizing fluid (DNF) was added to neutralize activity, diluted serially and 0.5 ml plated on TSA plates. Plates were incubated for 18-24 hrs at 37° C. Base formulation without additives was used as a control in place of test sample and processed similarly. The antibacterial activity was determined by calculating the difference in log 10 cfu/ml of test samples relative to control [PBS]. The results are shown in Table 4.
Control growth ranged from 5×105-1×106. It was observed that combinations of lemon extract, PHMB and octanediol showed synergistic activity with essential oils. The above data indicate that (1) of the extracts tested, only lemon extract appears to show synergistic activity with BAC; (2) BAC enhances the activity of essential oils (CN+LG+T); and (3) lemon extract+PHMB+alkanediols appear to exhibit synergism with essential oils.
The antibacterial activity of various test formulations were tested. The test formulations were prepared by adding active agents to the following base formulation, in the concentrations listed in Table 5A-F. Active ingredients were lemongrass oil (“LG”), cinnamon bark oil (“CN”), thymol (“T”), benzalkanoium chloride (“BAC”), polyhexamethylene biguanide (“PHMB”), octanediol (“0”), pentanediol (“P”), wasabi extract (“WE”), aspen bark extract (“AE”), lemon extract (“LE”), vanilla extract (“VE”), cetyl pyridinium chloride (“CPC”), and rosemary (“R”). Where necessary water was added to bring the total concentration to 100%.
Antibacterial activity against methicillin-resistant Staphylococcus aureus (“MRSA”) was tested using a 15 second exposure time (hereafter, “MRSA Rapid-Kill Assay”). Briefly, a tube-dilution method was used to evaluate samples as per the US FDA-Tentative Final Monograph (“TFM”) method. 0.9 ml of test sample was added to 0.1 ml of a bacterial culture containing 1×107 colony forming units per ml [cfu/ml] and vortexed for 15 seconds. 9 ml of Drug Neutralizing fluid (DNF) was added to neutralize activity, diluted serially and 0.5 ml plated on TSA plates. Plates were incubated for 18-24 hrs at 37° C. Base formulation without additives was used as a control in place of test sample and processed similarly. The antibacterial activity was determined by calculating the difference in log10 cfu/ml of test samples relative to control [PBS]. The results are shown in Tables 5A-F.
The above results indicate that of the plant extracts tested, vanilla and citrus extracts, which contain high concentrations of polyphenols (30-50% and above), exhibit significant synergism with low concentrations of biguanide (PHMB) (0.06%) and relatively lower synergism with 0.13% w/w of BAC. These extracts, along with BAC+PHMB with and without alkanediols, were observed to effect 100% kill of pathogens. Other extracts also enhanced the activity but not as significantly as LE and VE when used along with BAC+PHMB+O. Synergistic activity of these extracts at the use concentrations indicated above (0.3-0.6% w/w) were not observed to exhibit detectable odor as tested. Of note, the essential oils and thymol as used above did produce detectable odor.
In the above tests, essential oils at 0.1-0.3% did not show synergistic activity with BAC+PHMB with and without alkanediols. Combinations of low concentrations of essential oils and lemon or vanilla extract showed synergistic activity with PHMB+O against MRSA.
Botanical oral rinse “OCP-G1*” was prepared initially as two phases, A and B, which were then mixed:
Botanical oral rinse “OCP-G2*” was prepared initially as two phases, A and B, which were then mixed:
Botanical oral rinse “OCP-AIF*” was prepared initially as two phases, A and B, which were then mixed:
The antibacterial activities of oral rinses OCP-G1*, OCP-G2*, OCP-AIF* and commercially available GUM oral rinse (which contains 0.12 percent chlorhexidine) were measured after one minute contact with colonized bacteria on agar plates. For this test, 0.3 ml of microbial cultures of 105 cfu/ml were seeded on Sabouraud Dextrose Broth Plate (SDB) and incubated for 4 hours at 37° C. in order for the pathogens to tightly adhere and colonize the agar surface. 0.3 ml of oral rinses or PBS (for the control sample) were then added and spread onto various plates. After 1 minute, 1 ml drug inactivating media was added to the plate and swirled to cover the whole plate. The plates were then incubated at 37° C. for 24 hours. The colony counts on the plate were enumerated.
The antimicrobial activities of oral rinses OCP-G1*, OCP-G2*, OCP-AIF* and GUM against S. aureus and C. albicans, measured as set forth above, are presented in Table 6
S.
aureus
C.
albicans
In a specific non-limiting embodiment, an anti-inflammatory, anti-irritant topical gel is provided comprising the following ingredients:
The above gel was anecdotally tested by subjects for its effect on minor burn, mosquito bite, prickly heat, or dry skin; the results are subjective.
Table 7A shows the subjective effects of the gel on blister formation and redness after minor burn in three subjects (denoted #1, #2 and #3).
Table 7B shows the subjective effects of the gel on itch resulting from a mosquito bite in three subjects (denoted #4, #5, and #6).
Table 7C shows the subjective effects of the gel on itch resulting from prickly heat rash in three subjects (denoted #7, #8, and #9).
Table 7D shows the subjective effects of the gel on itch resulting from dry skin in three subjects (denoted #10, #11, and #12).
Table 7E shows the results of antimicrobial evaluation of a gel having a slightly different formula but having the same concentrations of tetrahydrocurcumanoid, PHMB, lemon/citrus extract, pomegranate oil, cinnamon oil, lemongrass oil, and rosemary oil (the formulation tested for Table 7E had witch hazel extract rather than portulaca extract), and compares that gel to a commercially available 2% miconazole cream.
P.
aeuroginosa
S.
aureus
C.
albicans
A hand sanitizer foam was tested comprising the following ingredients (“FOAM BSAM-4-1”):
A hand sanitizer lotion was tested having the following ingredients (“LOTION BASM-4-1”):
A rapid tube dilution (15 second time kill) method was used. 0.9 ml of the test sample was inoculated with bacterial culture 107 CFU/ml). After 15 seconds drug neutralizing fluid (DNF) was added to stop antimicrobial action. Serial dilutions were made and subcultured on Trypticase Soy Agar plates, incubated for 24-48 hours. Phosphate buffer saline was used as control.
The results of antimicrobial testing are presented in Table 8.
S.
aureus
P.
aeruginosa
E.
coli
A “SynBotanica First Aid Cream-1” was tested having the following ingredients:
Trypticase soy agar plates were seeded with 0.1 ml of 108 CFU bacteria and 107 C. albicans. Four wells of 0.7 cm were made on the plate using a cork borer. Each well was filled with 0.1 g of the cream, and the plates were incubated for 24 hrs at 37° C. The zones of inhibition were measured.
The results of antimicrobial testing are shown in Table 9.
S.
aureus
P.
aeruginosa
C.
albicans
This example demonstrates that botanical extracts such as vanilla extract and lemon extract exhibit synergistic antibacterial activity with PHMB. However, chlorhexidine, which is another biguanide, did not show such synergism.
14.1 Testing Method
Synergistic effect of botanical extracts and biguanides (Rapid kill method (108 S. aureus)): The antimicrobial effect of an oral rinse base, containing the ingredients described in table 10 below, were tested against a high concentration of bacteria. In a sterile culture tube, 0.1 ml of S. aureus (108 cfu/ml) was treated with 0.9 ml of test mouthrinse for 15 seconds. The reaction was stopped with Drug neutralizing Fluid (DNF) and then further diluted with the same media. 0.5 ml of the dilution was then plated on Tripticase Soy Agar (TSA) and incubated at 37° C. overnight. The colony counts were determined and the log 10 reduction from the control (phosphate-buffered saline (PBS) inoculated with the same culture) was calculated. This test shows the efficacy of the following ingredients in oral rinses in inactivating oral pathogens after a 15 second contact time.
Botanical extracts exhibit synergism specifically with PHMB.
14.2 Additional Examples of Oral Compositions are as Follows:
Optionally, anti-irritants selected from the group Brahmi extracts, Red sandal wood extracts, Curcumin compounds, Aloe products, Bisabolol, Rosemary oil, Chalmogra oil, oat powder/extract, Beta glucan, Chitosan. Calendula oil, Portulaca extract, Witch hazel extract, Pomegranate oil (0.1-2.0).
Oral rinse 15BCF
Oral rinse A2
Method 2: Antibacterial Activity of Oral Rinses after One Minute Contact with 6 h Colonized Bacteria on the Agar Plates.
For this test, 0.3 ml of microbial cultures of 106 cfu/ml were seeded on Trypticase Soy agar Plate (TSA) and incubated for 6 hours at 37° C. in order for the pathogens to tightly adhere and colonize the agar surface. 0.5 ml of oral rinses and PBS (for the control sample) was then added and spread on the surface of the plates. After 1 minute, 1 ml drug inactivating media was added to the plate and swirled to cover the whole plate and plates were then incubated at 37° C. for 24 hours. The colony counts on the plate were enumerated.
Candida albicans (0.3 ml of 106 cfu/ml) incubated for 6 h and treated with 0.5 ml of following oral rinse.
Group: C. albicans
Botanical extracts combined with PHMB exhibit antimicrobial effects against C. albicans.
15.1 Examples of Topical Antimicrobial Compositions Comprising Botanical Extracts, PHMB and Essential Oils (or Active Constituents Thereof) are Described Below.
Rapid (15 second) and broad spectrum antibacterial efficacy of Synbotanica soap and lotion were tested against various microorganisms. The ASTM E 2783-11 method for testing the antimicrobial efficacy using a time kill procedure was used. The rapid antibacterial activity (15 seconds exposure) of the SynBotanica soap and lotion was tested against various organisms listed in below tables and given with results.
Method 3: In a sterile culture tube, 0.1 ml of bacterial culture (106 cfu/ml) was treated with 0.9 ml of test sample for 15 seconds. The reaction was stopped with Drug neutralizing Fluid (DNF) and then further diluted with the same media. 0.5 ml of the dilution was then plated on Tripticase Soy Agar (TSA) and incubated at 37° C. overnight. The colony counts were determined and the log 10 reduction from the control (phosphate-buffered saline (PBS) inoculated with the same culture) was calculated.
Rapid and Broad Spectrum Antibacterial Efficacy of Triclosan free Syn-Botanica Soap-1 (also herein referred to as Hand disinfectant Soap-1) and Syn-Botanica lotion-1 (also herein referred to as Aqueous Hand Sanitizer Lotion-1), are shown in the table below:
S. aureus
P. aeruginosa
E. coli
MRSA
MRSA = Methicillin-resistant S. aureus; control growth ranged from 5 × 105 to 1 × 106 cfu/ml.
15.2 Additional Examples of Topical Compositions are as Follows:
Antibacterial activity against various bacteria after 1 minute exposure to oral rinse (OCP-1) containing PHMB and other oral rinses (Bacteria tested 105 cfu/ml) was tested. Bacteria were grown on agar plates for 4 hours with the test composition. Results are shown in Table 11 below:
MRSA
S. aureus
C. albicans
P. aeruginosa
Antibacterial activity against various bacteria after 1 minute exposure to oral rinses containing PHMB (0.1%, OCP-M) and GUM (106 cfu/ml) was tested. Bacteria were grown on agar plates for 6 hours with the test composition. Results are shown in Table 12 below:
MRSA
S. aureus
C. albicans
P. aeruginosa
Antimicrobial efficacy of the following alcohol-free hand sanitizers was tested:
S. aureus
P. aeruginosa
E. coli (35218)
MRSA (4716)
S. epidermidis
E. faecalis
S. marcescens
A. baumanni
E. aerogenes
K. pneumonia
S. typhimurium
C. albicans
Rapid (15 second) and broad spectrum antibacterial efficacy against various microorganisms were tested. ASTM E 2783-11 method for testing the antimicrobial efficacy using a time kill procedure was used. The rapid antibacterial activity (15 seconds exposure) of the hand foam and lotion was tested against various organisms listed in Table 11.
ATCC=American Type Culture Collection; MRSA=Methicillin-resistant S. aureus; VREF=Vancomycin-resistant E. faecalis. The control growth ranged from 5×105 to 1×106 cfu/ml.
Conclusion: Syn-Botanica hand sanitizer foam and lotion exhibit superior antimicrobial efficacy than Triclosan/PCMX hand cleansers.
Rapid and Persistent Antibacterial Efficacy of Syn-Botanica Hand Sanitizer by Pigskin Method which Simulates the Volunteer Method of the American Society for Testing and Materials ASTM E2755-10 (Test Organism: S. aureus)
Method: 3 cm2 pieces of pigskins were prepared and each piece was mounted on a petridish which simulates the band surface. Pigskins were contaminated with bacteria and rinsed with drug inactivating media. The colony counts in the rinse was determined by subculturing on agar plates and incubating for 24 hours at 37° C. (Baseline Counts). The same pair was then inoculated with bacteria and treated with the sanitizer and the bacterial counts were determined as before. The skin was again contaminated with bacteria and treated with the sanitizer and bacterial counts were determined as described above. Contamination and antibacterial product application were repeated 10 times. The bacterial counts were determined after the first and tenth applications. The reduction in bacterial counts after the first and tenth repeated cycles of contamination and product application, were compared to that of the Baseline Counts. Results are shown in the table below:
S.
aureus
Anti-inflammatory, anti itch and anti microbial topical cream/gel (SB AI-3) was tested. Evaluation of efficacy in human volunteers was determined.
P.
aeuroginosa
S.
aureus
C.
albicans
A novel botanical oral rinse (BOR-1) containing a synergistic combination of antimicrobial botanicals as well as anti inflammatory botanicals along with a non irritant preservative (PHMB) was developed. As described below, BOR-1 was found to be effective against plaque forming S. mutants. This oral rinse is also effective against ventilator associated pneumonia (VAP) causing pathogens. Evaluation of 0.12% chlorhexidine (CHX) solutions as a prophylactic prior to mechanical intubation has concluded that oral decontamination can reduce the risk of acquiring VAP. Although CHX has been used as an oral antiseptic, adverse effects, such as irritation of the oral mucosa, discoloration of teeth and altered taste perception have been reported with its use. (Gúrgan C A, Zaim E, Bakirsoy I, Soykan E. Short-Term Side Effects of 0.2% Alcohol-Free Chlorhexidine Mouth rinse Used as an Adjunct to Non-Surgical Periodontal Treatment: A Double-Blind Clinical Study. J Periodontol 2006; 77:370-384). Moreover, studies have indicated that CHX is cytotoxic to murine fibroblasts cell lines and to human dennal, gingival and osteoblastic cell lines (Lee T H, Hu C C, Lee S S, Chou M Y, Change Y C. Cytotoxicity of chlorhexidine on human osteoblastic cells is related to intracellular glutathione levels. Int Endod J 2010; 43:430-435). As described below, the rapid antibacterial activity of the novel oral rinse BOR-1, chlorhexidine-containing oral rinse (PerioRx), and Listerine was evaluated and compared.
BOR-1 displayed better rapid antimicrobial efficacy to that of the chlorhexidine-containing rinse especially against S. aureus MRSA, and C. albicans. BOR-1 when exposed for 24 hours to tightly adhered (grown for 4 hours on agar plate) organisms on agar plates showed similar efficacy to Chlorhexidine oral rinse. Listerine was not as effective. When these oral rinses were exposed for 1 minute to various organisms grown on Agar plates for 4 hours, only BOR was effective against all the organisms tested. In contrast, Chlorhexidine oral rinse was effective only against C. albicans. This botanical composition can also be incorporated in Toothpaste/gel and dental floss.
Symbotanica oral rinse (BOR-1)
To test the rapid antimicrobial efficacy of the mouth rinses against various bacteria, ASTM standard E 2783-11 method was used. Briefly, 0.1 ml of bacterial culture (107 cfu/ml) was added to 0.9 ml of test mouthwash, BOR-1 or control samples and mixed for 15 seconds. The reaction was stopped with drug neutralizing Fluid (DNF) and then serially diluted with the same media. 0.5 ml of the dilutions was then plated on Trypticase soy plate and incubated at 37° C. for 24-48 hours. The colony counts were determined and the log 10 reduction from the control (phosphate-buffered saline (PBS) inoculated with the same culture) was calculated.
S.
aureus
MRSA
S.
nutans
C.
albicans
P.
aeruginosa
BOR-1, Listerine and PerioRx (Chlorhexidine (0.12%)) are effective in rapidly inactivating Strept. mutans after a 15 second contact time. BOR-1 was more effective against all other pathogens.
For this test, 0.5 ml of microbial cultures of 104 cfu/ml were seeded on Trypticase Soy agar Plates (TSA) and incubated for 4 hours at 37° C. in order for the pathogens to tightly adhere and colonize the agar surface. 0.5 ml of oral rinses, and PBS (for the control sample) was then added and spread to cover the surface of the plates. The plates were then incubated at 37° C. for 24 hours. The colony counts on the plate were enumerated.
S.
aureus
MRSA
C.
albicans
P.
aeruginosa
Chlorhexidine, BOR-1 products were effective in killing colonized pathogens. Listerine was not effective on colonized pathogens except for C. albicans
In this method, 0.5 ml of oral rinses, or PBS (for the control sample) were first spread on TSA and incubated for 1 hour at 37° C. 0.3 ml×103 cfu/ml microbial cultures were then spread onto the plates, which were then incubated at 37° C. overnight. The colony counts were enumerated.
S.
aureus
MRSA
C.
albicans
P.
aeruginosa
Both Chlorhexidine and BOR-1 demonstrated excellent residual antimicrobial efficacy. Listerine was ineffective. This may be due to the evaporation of alcohol and the absence of antibacterial actives in the product to kill the pathogens
12 well-shaped cavities (6 wells each on right and left side of a TSA plate) were created in each plate with a cork borer. 0.3 ml×103 cfu/ml microbial cultures were then spread onto the plates and incubated for 1 hour. 0.5 ml of the oral rinses, and control (PBS) samples were spread on each plate. The colony counts on the surface as well as in the cavities were determined after overnight incubation. The colonies inside/underneath the cavities were distinguishable from colonies on the surface, because the penetrating colonies appeared superimposed to the colonies growing on the surface.
S.
aureus
MRSA
C.
albicans
P.
aeruginosa
S.
aureus
MRSA
C.
albicans
P.
aeruginosa
BOR-1 effectively killed both surface and penetrating pathogens for all the pathogens tested. Chlorhexidine rinse was less effective against C. albicans. Listerine was ineffective against all of the pathogens tested.
For this test, 0.5 ml of microbial cultures of S. mutant (108 cfu/ml) was seeded on Muller Hinton agar plate (MHA) and incubated for 5 days at 37° C. in order for the pathogens to tightly adhere and colonize the agar surface. On 5th day, 0.5 ml of oral rinses and PBS (for the control sample) were then added and spread onto various plates, After 1 minute, 1 ml drug inactivating media was added to the plate and swirled to cover the whole plate and kept for 5 minutes. All the bacterial colonies were collected from the plates using a liquid media and sub cultured on another plate and was then incubated at 37° C. for 48 hours. The colony counts on the plate were enumerated.
BOR-1 displayed superior, rapid antimicrobial efficacy when compared to that of the other oral rinses tested. The testing indicates that a 15 second rinse would eliminate loosely adhered bacteria in the oral cavity. Furthermore, when exposure times were longer (24 hours), BOR-1 showed similar or more antimicrobial activity against tightly adhered organisms than that of the chlorhexidine-containing rinse. BOR-1 may be potent and safer alternatives to Listerine or chlorhexidine containing oral rinses for general use as well as in the prophylaxis of ventilator-associated pneumonia.
The antimicrobial efficacy of a composition comprising biguanides and fennel oil, thyme oil/thymol and/or vanilla oil was tested against S. aureus (107 cfu/ml). The compositions were tested to demonstrate that the antimicrobial activity of Enhancement of biguanides is enhanced by fennel oil, thyme oil/thymol and/or vanilla oil.
In-vitro study Test organism: S. aureus (107 cfu/ml)
The ingredients listed in the following experiments 1 and 2 were incorporated into Base A and tested for antimicrobial efficacy using the method described below:
The volume of all the above compositions after incorporation in Base A was adjusted to 100% with water.
Chlorhexidine exhibits synergistic activity when combined with either thymol or basil oil. Furthermore, the combination of either fennel seed oil and thymol or fennel seed oil, thymol and vanilla oil with chlorhexidine also exhibited synergistic activity.
The volume of all the above compositions after incorporation in Base A was adjusted to 100% with water.
PHMB exhibited synergistic activity when combined with either thymol or vanilla oil. Furthermore, the combination of either fennel seed oil and thymol or fennel seed oil, thymol and vanilla oil with PHMB also exhibited synergistic activity.
Plate Method: Rapid Anti-Microbial Efficacy of Oral Rinses Exposed to 4 Hour Incubated Culture (S. aureus):
0.3 ml of S. aureus culture (105 cfu/mL) or Candida albicans (105 cfu/ml) was seeded on TSA plates and incubated for 4 hours at 37° C. in such that the order microorganisms adhered tightly to the plates and colonized the surface of the plates. 0.5 ml of test oral rinses or PBS (control) was then added and spread on the surface of the plates. After 1 minute, 2.5 mL of Drug Neutralizing Fluid (DNF) was added, swirled to cover whole plate, and transferred into sterile culture tubes. 2 ml of DNF was added to rinse the plate thoroughly and transferred into the same culture tube. The tube was vortexed and serially diluted to facilitate colony counting. 0.5 ml of the last dilution was plated on trypticase soy agar plates (TSA), which were incubated at 37° C. for 24 hours and the colony counts (cfu)/ml were determined.
Experiment 1A: Test organism: S. aureus (105 cfu/ml)
Both of the PTFV and CTFV oral rinses exhibited higher anti-bacterial efficacy against S. aureus compared to control. Furthermore, addition of vanilla extract (0.3%) to both of the PTFV and CTFV oral rinses (PTFV-E and CTFV-E) enhanced the anti-bacterial efficacy against S. aureus.
Experiment 2A: Test Organism: Candida albicans (105 cfu/ml)
Both of the PTFV and CTFV oral rinses exhibited higher anti-bacterial efficacy against Candida albicans compared to control. Furthermore, addition of vanilla extract (0.3%) to the CTFV oral rinse (CTFV-E) enhanced the anti-bacterial efficacy against Candida albicans.
Various patents and publications are cited herein, the contents of which are hereby incorporated by reference in their entireties herein.
This application is a continuation of International Patent Application Serial No. PCT/US2013/071731, filed Nov. 25, 2013, which claims priority to U.S. Provisional Application Ser. No. 61/736,932, filed Dec. 13, 2012, and U.S. Provisional Application Ser. No. 61/831,510, filed Jun. 5, 2013, to each of which priority is claimed, and the contents of each of which are incorporated by reference in their entireties.
| Number | Date | Country | |
|---|---|---|---|
| 61736932 | Dec 2012 | US | |
| 61831510 | Jun 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US13/71731 | Nov 2013 | US |
| Child | 14735051 | US |
